An Observational Long-term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy Read more
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial) Read more
Analysis of Checkpoint Inhibitors as Post-Transplant Consolidation in Relapsed/Refractory and High-Risk Multiple Myeloma Read more
A Phase 3, randomized, open-label study of belantamab mafodotin administered in combination with lenalidomide and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (TI-NDMM)-DREAMM-10 Read more
A Phase 1 Study of an oral, first-in-class, selective, and potent MMSET catalytic inhibitor that suppresses H3K36me2 in patients with Relapsed and Refractory Multiple Myeloma Read more
Real-World Experience with BCMA-directed therapies for patients with relapsed and refractory multiple myeloma. Read more
